These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17537237)

  • 21. Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29.
    Zhou M; Huang K; Jung KJ; Cho WK; Klase Z; Kashanchi F; Pise-Masison CA; Brady JN
    J Virol; 2009 Jan; 83(2):1036-44. PubMed ID: 18971272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Techniques to analyze the HIV-1 Tat and TAR RNA-dependent recruitment and activation of the cyclin T1: CDK9 (P-TEFb) transcription elongation factor.
    Gomes N; Garber ME; Jones KA
    Methods Enzymol; 2003; 371():324-36. PubMed ID: 14712711
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of the position of TAR on transcriptional activation by HIV-1 Tat in vivo.
    Wright S; Luccarini C
    J Mol Biol; 1996 Oct; 263(1):1-7. PubMed ID: 8890908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator.
    Marcello A; Zoppé M; Giacca M
    IUBMB Life; 2001 Mar; 51(3):175-81. PubMed ID: 11547919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Latent HIV-1 TAR Regulates 7SK-responsive P-TEFb Target Genes and Targets Cellular Immune Responses in the Absence of Tat.
    Eilebrecht S; Benecke BJ; Benecke AG
    Genomics Proteomics Bioinformatics; 2017 Oct; 15(5):313-323. PubMed ID: 29037489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TAR-independent activation of HIV-1 requires the activation domain but not the RNA-binding domain of Tat.
    Taylor JP; Kundu M; Khalili K
    Virology; 1993 Aug; 195(2):780-5. PubMed ID: 8337844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.
    Bieniasz PD; Grdina TA; Bogerd HP; Cullen BR
    EMBO J; 1998 Dec; 17(23):7056-65. PubMed ID: 9843510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation.
    Kwak YT; Ivanov D; Guo J; Nee E; Gaynor RB
    J Mol Biol; 1999 Apr; 288(1):57-69. PubMed ID: 10329126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.
    Yang Z; Yik JH; Chen R; He N; Jang MK; Ozato K; Zhou Q
    Mol Cell; 2005 Aug; 19(4):535-45. PubMed ID: 16109377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1.
    Zhang J; Tamilarasu N; Hwang S; Garber ME; Huq I; Jones KA; Rana TM
    J Biol Chem; 2000 Nov; 275(44):34314-9. PubMed ID: 10944537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription.
    Ammosova T; Washington K; Debebe Z; Brady J; Nekhai S
    Retrovirology; 2005 Jul; 2():47. PubMed ID: 16048649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation.
    Richter S; Cao H; Rana TM
    Biochemistry; 2002 May; 41(20):6391-7. PubMed ID: 12009901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR.
    Sedore SC; Byers SA; Biglione S; Price JP; Maury WJ; Price DH
    Nucleic Acids Res; 2007; 35(13):4347-58. PubMed ID: 17576689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A minimal chimera of human cyclin T1 and tat binds TAR and activates human immunodeficiency virus transcription in murine cells.
    Fujinaga K; Irwin D; Taube R; Zhang F; Geyer M; Peterlin BM
    J Virol; 2002 Dec; 76(24):12934-9. PubMed ID: 12438619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).
    Chiu YL; Cao H; Jacque JM; Stevenson M; Rana TM
    J Virol; 2004 Mar; 78(5):2517-29. PubMed ID: 14963154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription.
    O'Keeffe B; Fong Y; Chen D; Zhou S; Zhou Q
    J Biol Chem; 2000 Jan; 275(1):279-87. PubMed ID: 10617616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional differences between human and bovine immunodeficiency virus Tat transcription factors.
    Bogerd HP; Wiegand HL; Bieniasz PD; Cullen BR
    J Virol; 2000 May; 74(10):4666-71. PubMed ID: 10775603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.
    Zhou M; Halanski MA; Radonovich MF; Kashanchi F; Peng J; Price DH; Brady JN
    Mol Cell Biol; 2000 Jul; 20(14):5077-86. PubMed ID: 10866664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression.
    Fujinaga K; Irwin D; Geyer M; Peterlin BM
    J Virol; 2002 Nov; 76(21):10873-81. PubMed ID: 12368330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function.
    Liou LY; Herrmann CH; Rice AP
    J Virol; 2002 Nov; 76(21):10579-87. PubMed ID: 12368300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.